Teleflex Incorporated
TFXHealthcareNASDAQMedical Instruments & Supplies · Last scanned Oct 26, 2026
Scan Results
Daily timeframeTeleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the. With a market capitalization of $5.77B, it sits in mid-cap territory. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and collection of blood samples; intraosseous access systems consisting of EZ-IO intraosseous vascular access systems, and Arrow FAST1 sternal intraosseous infusion systems; and hemostatic products, including external hemostats and trauma products under the QuikClot brand.
Market Cap
$5.77B
Beta
0.83
P/E (TTM)
—
P/E (Fwd)
12.45
EPS (TTM)
$-8.48
EPS (Fwd)
$10.94
ROE
-0.7%
ROA
1.8%
Cash
$323.9M
Total Debt
$2.94B
Free CF
$179.5M
52W Change
2.8%
Annual Financials
Cash vs Debt
Where TFX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, TFX finished 0.91% above its 150-day moving average ($128.51) and 4.80% above its 200-day moving average ($123.74). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TFX overbought or oversold?
At the October 20, 2026 close, TFX's RSI(14) was 59.2, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $323.9M in cash, though total debt stands at $2.94B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $179.5M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -0.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.8% is on the lower side, which is common in asset-heavy industries. Revenue has pulled back from $2.79B (2022) to $1.99B (2025), a 29% decline worth watching.
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Teleflex Incorporated and its sector.